Condition
Anaplastic Large Cell Lymphoma, ALK-Positive clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Anaplastic Large Cell Lymphoma, ALK-Positive clinical trials that are recruiting, at sites in 3 countries (most in United States (3), France (1), Netherlands (1)). By phase: Phase 1/2 (1), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Anaplastic Large Cell Lymphoma, ALK-Positive clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Nivolumab plus chemotherapy for ALK+ relapsed/refractory ALCL in kids, teens, and young adults | Phase 2 | Valhalla, New York | Recruiting | Jun 10, 2025 |
| Banked C7R-modified allogeneic CD30-targeted CAR T cells for CD30-positive lymphomas | Phase 1 | Houston, Texas and 1 other locations | Recruiting | Dec 20, 2023 |
| Registry for individuals with T-cell lymphoma | — | Duarte, California and 25 other locations | Recruiting | Aug 7, 2023 |
| Brigatinib treatment for young patients with specific cancers | Phase 1/2 | Paris and 1 other locations | Recruiting | Jun 14, 2021 |
All recruiting trials (4)
-
Nivolumab plus chemotherapy for ALK+ relapsed/refractory ALCL in kids, teens, and young adults
This trial tests whether adding nivolumab to chemotherapy, followed by reduced-dose chemoimmunotherapy and a stem cell transplant, can improve outcomes for young patients with relapsed or refractory ALK-positive ALCL.
-
Banked C7R-modified allogeneic CD30-targeted CAR T cells for CD30-positive lymphomas
This will try a donated (banked) C7R.CD30.CAR-EBVST cell infusion to treat people aged 12–75 whose CD30-positive lymphoma has returned or not responded to prior treatments.
-
Registry for individuals with T-cell lymphoma
This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.
-
Brigatinib treatment for young patients with specific cancers
This study is testing the right dose of brigatinib to see if it can help young patients with certain types of cancers, like ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumors.
Related topics
Quick answers
How many Anaplastic Large Cell Lymphoma, ALK-Positive clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (3 trials), France (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.